SlideShare a Scribd company logo
1 of 9
Download to read offline
―Going beyond the pill – Can technology enhance
the role of pharmaceutical products in the treatment
of chronic diseases‖
The opportunity and the challenge
A growing demand for healthcare

People are living longer.

Patient populations are growing in emerging markets.

Many diseases are still not well managed.


Can increased use of technology aid in delivering healthcare to
populations?




2
A growing body of evidence on
adherence!


   “Increasing the effectiveness of
   adherence interventions may
   have a far greater impact on
   the health of the population
   than any improvement in
   specific medical treatments”
   WHO Report, 2003




                                      “20% of initial scripts are
                                      never filled, and 40% to 70%
                                      of those patients who fill a
                                      script drop off therapy after
                                      four months” AZ Funded Market
                                      Research, 2005
An example of unmet need




     Management of diabetic patients is approx 15% of national healthcare budget
     80% of this budget is spent on the downstream consequences of poor control
Are We Moving To A New
Paradigm In Healthcare?
How far have we moved already?




                                                       Use of data to
                                                            tailor
                                    Sophisticated     interventions to
                                      medication       maximise the
                                   reminder, additi      benefit of a
                                     onal disease       treatment on
                        Patient    management, h       overall health
                     information      ealthcare           outcomes
                    services and     services and
                     medication        outcome
                       reminder        reporting
      Access to
      patient
      information
Who Will Intelligent Pharma Benefit?



                Intelligent Pharmaceuticals will help patients to take
  Patients
                control of their illnesses and wellness.




                The additional data provided by Intelligent
Healthcare
                Pharmaceuticals will help physicians to monitor their
practitioners
                patients and adjust treatment as appropriate




                Improved adherence and increased data will help
 Caregivers
                caregivers to look after the patient




   Payers       Increased adherence will decrease costs for payers
―...achieving effective blood pressure
control would be approximately
equivalent to eliminating all
deaths from accidents, or from
influenza and pneumonia combined.‖

—David Cutler, Harvard University

More Related Content

More from Technology Ventures Event - MMUBS / DBMS (9)

Manchester mHealth Ecosystem
Manchester mHealth EcosystemManchester mHealth Ecosystem
Manchester mHealth Ecosystem
 
Health 4.0 Platforms
Health 4.0 PlatformsHealth 4.0 Platforms
Health 4.0 Platforms
 
A Journey from Patient Needs to Health Solutions
A Journey from Patient Needs to Health SolutionsA Journey from Patient Needs to Health Solutions
A Journey from Patient Needs to Health Solutions
 
High Performing Crowds in Healthcare
High Performing Crowds in HealthcareHigh Performing Crowds in Healthcare
High Performing Crowds in Healthcare
 
Innovation in eLearning
Innovation in eLearningInnovation in eLearning
Innovation in eLearning
 
Market-led R&D
Market-led R&DMarket-led R&D
Market-led R&D
 
Intellectual Property in Engineering
Intellectual Property in EngineeringIntellectual Property in Engineering
Intellectual Property in Engineering
 
A Vision for UK Higher Education
A Vision for UK Higher EducationA Vision for UK Higher Education
A Vision for UK Higher Education
 
Past, Present and Future of Innovation
Past, Present and Future of InnovationPast, Present and Future of Innovation
Past, Present and Future of Innovation
 

AstraZeneca - Digital Technology in Pharma

  • 1. ―Going beyond the pill – Can technology enhance the role of pharmaceutical products in the treatment of chronic diseases‖
  • 2. The opportunity and the challenge A growing demand for healthcare People are living longer. Patient populations are growing in emerging markets. Many diseases are still not well managed. Can increased use of technology aid in delivering healthcare to populations? 2
  • 3. A growing body of evidence on adherence! “Increasing the effectiveness of adherence interventions may have a far greater impact on the health of the population than any improvement in specific medical treatments” WHO Report, 2003 “20% of initial scripts are never filled, and 40% to 70% of those patients who fill a script drop off therapy after four months” AZ Funded Market Research, 2005
  • 4.
  • 5. An example of unmet need Management of diabetic patients is approx 15% of national healthcare budget 80% of this budget is spent on the downstream consequences of poor control
  • 6. Are We Moving To A New Paradigm In Healthcare?
  • 7. How far have we moved already? Use of data to tailor Sophisticated interventions to medication maximise the reminder, additi benefit of a onal disease treatment on Patient management, h overall health information ealthcare outcomes services and services and medication outcome reminder reporting Access to patient information
  • 8. Who Will Intelligent Pharma Benefit? Intelligent Pharmaceuticals will help patients to take Patients control of their illnesses and wellness. The additional data provided by Intelligent Healthcare Pharmaceuticals will help physicians to monitor their practitioners patients and adjust treatment as appropriate Improved adherence and increased data will help Caregivers caregivers to look after the patient Payers Increased adherence will decrease costs for payers
  • 9. ―...achieving effective blood pressure control would be approximately equivalent to eliminating all deaths from accidents, or from influenza and pneumonia combined.‖ —David Cutler, Harvard University